TLDR:
- BrickBio, a biotechnology company in Boston, received an investment from Samsung Ventures.
- The investment amount was not disclosed, but it will support the development of protein engineering technology and preclinical assets.
BrickBio, a Boston-based biotechnology company, has received an investment from Samsung Ventures. The exact amount of the investment was not disclosed, but it was made by Samsung Life Science Fund, a joint effort between Samsung Biologics, Samsung Bioepis, and Samsung C&T and managed by Samsung Ventures. The funding will be used to further advance their protein engineering technology and preclinical assets.
BrickBio, led by CEO John Boyce, focuses on developing precision biologics using an expanded genetic code. They offer a site-specific and site-selective platform that spans prokaryotic and eukaryotic expression systems, allowing for the development of unique biologics and protein therapeutics with enhanced characteristics. The company is expanding its therapeutic programs to include ADCs, bispecific conjugates, and novel scaffolds.
